ArticleInternational ophthalmology2023
One-year refractive outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity.
Article in International ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 3 citations in OpenAlex.
- Impact of anti-VEGF therapy versus laser therapy on mortality and treatment outcomes in retinopathy of prematurity: A systematic review and meta-analysis.Acta ophthalmologica · 2026Pooled it
- Refractive outcomes following anti-VEGF, vitrectomy, cryotherapy, and laser photocoagulation for retinopathy of prematurity: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Association of retinopathy of prematurity with early refractive development in mid-preterm infants.Eye (London, England) · 2026Article
- Long-Term Sequelae of Retinopathy of Prematurity-A Scoping Review.Children (Basel, Switzerland) · 2026Review
- A Review of Refractive Errors Post Anti-Vascular Endothelial Growth Factor Injection and Laser Photocoagulation Treatment for Retinopathy of Prematurity.Journal of clinical medicine · 2025Review
- Construction of a nomogram model to predict the risk of retinopathy of prematurity reactivate after intravitreal anti-vascular endothelial growth factor therapy: a retrospective study.Frontiers in pediatrics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the effects of laser photocoagulation (LPC) and intravitreal bevacizumab (IVB) therapy used in the treatment of retinopathy of prematurity (ROP) on the first age refraction values in our center.
methodsThe preterm infants who received LPC (Group I) and IVB therapy (Group II) for ROP were evaluated, and the refraction results were retrospectively compared.
resultsThe study included 86 eyes of 45 infants with a mean birth week of 26.5 ± 2.1 weeks and a mean birth weight of 904 ± 223 g. Treatments were administered up to a mean PMA of 36.0 ± 2.4 and 35.3 ± 2.6 weeks in Group I and Group II, respectively. In the follow-up examinations, 1-year spherical, cylindrical, and spherical equivalent (SE) values were 0.1 ± 2.2 D, - 1.2 ± 0.9 D, and - 0.5 ± 2.0 D in Group I and 1.3 ± 1.7 D, - 1.1 ± 0.8 D, and 0.8 ± 1.7 D in Group II, respectively (P = 0.018 for spherical; P = 0.772 for cylindrical, and P = 0.009 for SE). The mean spherical power and SE were significantly higher in Group II for zone II disease (p = 0.005 and p = 0.002). In addition, according to the ROP stage, infants with Stage 3 ROP were found to be significantly more myopic than infants in Stage 2 ROP in Group I (p = 0.03).
conclusionIn conclusion, this study supports that even 0.625 mg IVB for ROP causes less myopia compared to LPC. Consistent with the literature, it was observed that the stage and zone of ROP had a significant effect on the development of myopia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.